Investment Thesis
Acrivon is a pre-revenue biotech company with severe cash burn, consuming $49.9M in free cash flow annually against only $35.4M in available cash, indicating critical runway constraints. The company exhibits clinical-stage pharmaceutical characteristics with no meaningful revenue generation, negative operating margins exceeding -64M, and deteriorating returns on both equity (-45.8%) and assets (-40.6%), making it fundamentally unprofitable.
ACRV Strengths
- Strong liquidity position with 8.75x current ratio providing near-term operational flexibility
- Solid balance sheet with equity of $128.6M and minimal debt obligations (0.0x debt-to-equity)
- Notable insider activity with 17 Form 4 filings suggesting active management engagement
ACRV Risks
- Critical cash burn rate of $49.9M annually against $35.4M cash reserves indicates less than 9 months of operations before insolvency without capital raises
- Complete absence of revenue with no clear path to profitability in near-to-medium term typical of pre-clinical stage therapeutics
- Persistent operating losses of -$64M and negative ROE/ROA of -45.8% and -40.6% respectively demonstrate fundamental unprofitability and value destruction
Key Metrics to Watch
- Quarterly cash burn rate and cash runway (critical for survival threshold)
- Clinical trial progression and regulatory milestone achievements for pipeline drugs
- Equity dilution from future capital raises and impact on share count and ownership
ACRV Financial Metrics
ACRV Profitability Ratios
ACRV Balance Sheet & Liquidity
ACRV 5-Year Financial Trend
5-Year Trend Summary: Acrivon Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.74 indicates the company is currently unprofitable.
ACRV Growth Metrics (YoY)
ACRV Capital Allocation
ACRV SEC Filings
Access official SEC EDGAR filings for Acrivon Therapeutics, Inc. (CIK: 0001781174)